[Mechanisms of regulating monoamine oxidase activity in different brain regions]. 1980

S V Petrenko, and A I Balakleevskiĭ

Both in vitro and in vivo rates of oxidative deamination of 3H-dopamine (DA), 14C-tyramine (T), 14C-noradrenaline (NA), 3H-serotonine (S) and benzylamine (BA) by monoamine oxidases of homogenates of rat brain cortex, brain stem and basal ganglia were shown to be different either after administration of l-dihydroxyphenylalanine (l-DOPA) and of N1-d,l-seryl-N2/(2,3,4-trihydroxybenzyl) hydrazine (Ro 4-4602) or after their simultaneous administration into the animals. L-DOPA and Ro 4-4602, administered intraperitoneally at a dose of 50 mg/kg, did not affect distinctly the NA and S deamination in various parts of brain. Ro 4-4602 inhibited selectively the BA deamination in basal ganglia; simultaneous administration of the drug together with l-DOPA caused more pronounced inhibition of BA deamination; it decreased also the rate of deamination of DA and T in the ganglia. L-DOPA, Ro 4-4602 and their combination were especially effective at concentration 10(-4) M. These data characterize one of possible mechanisms of distinct antiparkinsonic action of these drugs. Ro 4-4602 was shown to inhibit the deamination of DA and S noncompetitively. L-DOPA (10(-5)--10(-4) M) activated selectively the DA deamination in brain mitochondria.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D001933 Brain Stem The part of the brain that connects the CEREBRAL HEMISPHERES with the SPINAL CORD. It consists of the MESENCEPHALON; PONS; and MEDULLA OBLONGATA. Brainstem,Truncus Cerebri,Brain Stems,Brainstems,Cerebri, Truncus,Cerebrus, Truncus,Truncus Cerebrus
D002540 Cerebral Cortex The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulci. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions. Allocortex,Archipallium,Cortex Cerebri,Cortical Plate,Paleocortex,Periallocortex,Allocortices,Archipalliums,Cerebral Cortices,Cortex Cerebrus,Cortex, Cerebral,Cortical Plates,Paleocortices,Periallocortices,Plate, Cortical
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide

Related Publications

S V Petrenko, and A I Balakleevskiĭ
October 1983, Mechanisms of ageing and development,
S V Petrenko, and A I Balakleevskiĭ
January 1972, Voprosy meditsinskoi khimii,
S V Petrenko, and A I Balakleevskiĭ
October 1984, Biochemical pharmacology,
S V Petrenko, and A I Balakleevskiĭ
January 1995, Neurotoxicology and teratology,
S V Petrenko, and A I Balakleevskiĭ
January 2008, Advances in gerontology = Uspekhi gerontologii,
S V Petrenko, and A I Balakleevskiĭ
January 1989, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology,
S V Petrenko, and A I Balakleevskiĭ
May 1982, Pharmacological research communications,
Copied contents to your clipboard!